Stryker Corporation (NYSE:SYK) traded at around $275 on October 7, down 1.01% on the day and 24.85% lower over twelve months. The company said on October 6 that Kevin Lobo will become executive chairman and Spencer Stiles will become chief executive, both effective January 1.
The succession arrives with the shares 30% below their 52-week high of $392.55.
READ ALSO: What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
The Numbers Do Not Explain the Share Price:
A chief executive handover after a fall that size usually follows a weak set of results.
That is not what the accounts show here. Revenue grew 9.40% in the most recent quarter, and earnings grew 44.30%. Gross margin is 65.59% and operating margin is 27.02%, both of which are ordinary for medical devices in a good year.
The cash statement is the strongest part. Free cash flow of $4.70 billion arrived against $3.73 billion of net income. A company collecting more cash than it reports as profit is not in operational difficulty.
Return on equity of 16.51% against return on assets of 8.16% shows a balance sheet carrying its weight rather than straining.
In January we ranked ten stocks for high returns. The one we put first has returned almost 30% since.
What the Market Repriced Instead:
If the results are intact, then the decline is about what the results are expected to be worth. The multiples show exactly that. The stock trades at 28.84 times trailing earnings and 16.49 times forward.
That gap says the market expects earnings to rise sharply and is unwilling to pay for the increase in advance. A PEG ratio of 1.30 is the same point expressed against growth, and it is no longer a demanding figure.
Hospital capital budgets are the mechanism. Elective procedure volumes set the reorder rate for implants, and those budgets move with reimbursement rather than with the economy. Short interest of 2.09% of the float is low, so the decline was selling by holders rather than positioning by sellers. In May we ranked this year’s best dividend performers. The one that finished first has since fallen 38%.
The Valuation Case:
Sustainability rests on procedure volumes, which neither the outgoing nor the incoming chief executive controls. On price, the stock sits at 16.49 times forward earnings, against 28.84 times trailing and 4.40 times book value.
Enterprise value to EBITDA of 15.94 counts the $15.45 billion of debt and is the fuller measure. The dividend yields 1.28% on a $3.52 rate and consumes 36.06% of earnings, so the payout is not the constraint here.
Conclusion:
The handover is not a response to the operating numbers. Revenue grew 9.40%, earnings grew 44.30%, and free cash flow of $4.70 billion exceeded $3.73 billion of net income, which is a business working as intended. However, the shares are 30% below their 52-week high, and the forward multiple of 16.49 against 28.84 trailing shows the market will not pay for the recovery before it arrives. Spencer Stiles inherits that gap on January 1. The number to watch is operating margin, because 27.02% is what the new chief executive has to defend first.
Market Sentiment:
Stryker Corporation was held by 72 hedge funds with a combined stake value of about $3.53 billion at the end of Q2 2026 in the Insider Monkey database. This is down from 81 hedge fund holders with a cumulative investment value of around $3.67 billion in the previous quarter.
While we acknowledge the risk and potential of SYK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SYK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price and What is eBay’s (EBAY) Economic Moat, and is it Widening or Narrowing?
This article is originally published at Insider Monkey.
